# US 2025/0144046 A1 · Pharmaceutical compositions and methods of administration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144046 A1
- Document ID: US20250144046A1
- Status: Published application
- Kind: A1
- Application number: 18/833,526
- Filed: 2023-01-27
- Published: 2025-05-08
- Earliest claimed: 2022-01-28
- Assignees: Metastx, LLC
- Applicants: Metastx, LLC
- Inventors: David CRICH; Somanath SHENOY; Brian CUMMINGS; Harvey D. HOMAN; Daniel A. GESELOWITZ
- Web page: https://patentgrep.com/patent/US20250144046A1

## CPC

- A61K 31/10: Sulfides; Sulfoxides; Sulfones
- A61K 31/05: Phenols {(cannabinoids A61K31/658)}
- A61P 35/00: Antineoplastic agents
- C07C 39/14: with at least one hydroxy group on a condensed ring system containing two rings
- C07C 323/16: the carbon skeleton containing six-membered aromatic rings
- C07C 323/21: with the sulfur atom of the thio group bound to a carbon atom of a six-membered aromatic ring being part of a condensed ring system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The present disclosure describes novel compounds and compositions and methods of making and using thereof related that are capable of inhibiting PAK1 and associated diseases or disorders, including tumors and cancerous cells. The inventive compounds are more efficacious and stable than IPA-3 without needing liposomal formulations as vehicles for the compounds.

## Claims

### Claim 1

A compound having the structure:
or a pharmaceutically acceptable salt thereof,
wherein W and V are each independently H or OH;
wherein X and Y are each independently an attachment site, methine, methylene, N, N-alkyl, N-acyl, N-sulfonyl, O, S, CO, or SO2, with the provisos that X and Y cannot both be an attachment site, O, S, or SO2 and that if X or Y is methine, X and Y are both methines to form a double bond;
wherein the alkyl group of the N-alkyl and N-acyl groups is a C1-C6 alkyl group that is linear or branched, unsubstituted or substituted, with one or more substitutions selected from the group consisting of hydroxyl groups, halogens, cyano groups, amines, and mixtures thereof; and
wherein Z is CHR where R is H or C1-C6 alkyl, wherein the C1-C6 alkyl group of Z is linear or branched, unsubstituted or substituted, with one or more substitutions selected from the group consisting of hydroxyl groups, halogens, cyano groups, amines, and mixtures thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein X is an attachment site.

### Claim 3 (depends on 1)

The compound of claim 1, wherein the compound is Compound 1:
or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

The compound of claim 1, wherein the compound is Compound 3:
or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The compound of claim 1, wherein the compound is Compound 4:
or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

A composition comprising:
the compound of claim 1 or a pharmaceutically acceptable salt thereof; and
one or more pharmaceutically acceptable excipients.

### Claim 7 (depends on 1, 5)

The composition of claim 5, wherein the composition comprises an effective amount of the compound of claim 1.

### Claim 8 (depends on 5)

The composition of claim 5, wherein the composition comprises a liposomal formulation.

### Claim 9 (depends on 5)

The composition of claim 5, wherein the composition does not comprise a liposomal formulation.

### Claim 10 (depends on 1)

A method of treating a disease or disorder associated with PAK1 comprising administering an effective amount of the compound of claim 1.

### Claim 11 (depends on 7)

The method of claim 7, wherein the compound is Compound 1:
or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 7)

The method of claim 7, wherein the compound is Compound 3:
or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 7)

The method of claim 7, wherein the compound is Compound 4:
or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 1)

A method of treating cancerous cells comprising administering an effective amount of the compound of claim 1.
